Obenomics is a pharmaceutical company focused on developing effective and safe therapeutic products for treating obesity and related metabolic syndromes. Obenomics is founded on the basis of new discovery and understanding of obesity and related metabolic syndromes. With robust animal mechanism-based proof of concept and preclinical safety data, one unique feature of Obenomics’ strategy is to modulate multiple signaling pathways by targeting epigenetic modification. The other feature is to specifically target the cellular origin of obesity, ie, adipose tissue.

Obenomics’ key technologies are based on patent applications directed to a novel target, the proof of concept for its anti-obesity effect in tissue-specific gene knockout mice, and compositions of novel compounds for treating obesity and related metabolic syndromes. Obenomics’ proprietary compounds are designed to target a single epigenetic modifier peripherally, for example, in mature adipocytes,to recapitulate the anti-obesity effect in the mouse model. Obenomics is currently seeking funding and collaborations to support the effort on in silico drug design, synthesis of novel compounds, and screen and validation of lead compounds using in vitro and in vivo assays.